These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21976243)

  • 21. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
    Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The current role of haematopoietic stem cell transplantation in the treatment of lymphomas--review].
    Válková V; Trnený M
    Klin Onkol; 2010; 23(3):155-64. PubMed ID: 20608325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
    Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
    Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
    Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
    Riedell PA; Bishop MR
    Bone Marrow Transplant; 2018 Jan; 53(1):11-21. PubMed ID: 28967896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.
    Lee JH; Lee JH; Kang YK; Lee JS; Kim WK; Lee KH
    Haematologica; 2001 Oct; 86(10):1114-5. PubMed ID: 11602425
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of mantle cell lymphoma: current approach and future directions.
    Brody J; Advani R
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):257-65. PubMed ID: 16751087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cell transplantation for lymphoma patients with HIV infection.
    Michieli M; Mazzucato M; Tirelli U; De Paoli P
    Cell Transplant; 2011; 20(3):351-70. PubMed ID: 20875226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment outcome of hematopoietic stem cell transplantation for malignant lymphoma].
    Tanosaki R
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1322-30. PubMed ID: 16097587
    [No Abstract]   [Full Text] [Related]  

  • 33. Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
    Rifkind J; Mollee P; Messner HA; Lipton JH
    Leuk Lymphoma; 2005 Feb; 46(2):217-23. PubMed ID: 15621804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
    Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
    Sureda A
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis.
    Loke J; Ward J; Mahendra P; Chaganti S; Malladi R
    Bone Marrow Transplant; 2013 Nov; 48(11):1486-7. PubMed ID: 23749106
    [No Abstract]   [Full Text] [Related]  

  • 38. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.